Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.58 |
| ▸ | PPARA | Q07869 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935594 | 0.99 | PPARG (0.73) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL6358469 | 0.98 | PPARG (0.71) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL5935648 | 0.90 | PPARG (0.60) | PPARGFFAR1PPARACYP3A4RXRA | |
| Hydrochloric Acid SCHEMBL5935818 | 0.90 | PPARG (0.59) | PPARGFFAR1PPARACYP3A4RXRA | |
| SCHEMBL6356577 | 0.89 | PPARG (0.68) | PPARGFFAR1PPARA | |
| SCHEMBL5935692 | 0.88 | PPARG (0.69) | PPARGFFAR1PPARA | |
| SCHEMBL6356578 | 0.87 | PPARG (0.68) | PPARGFFAR1PPARA | |
| SCHEMBL7196523 | 0.86 | PPARG (0.54) | PPARGFFAR1PPARA | |
| SCHEMBL5844579 | 0.85 | PPARG (0.80) | PPARGFFAR1PPARA | |
| SCHEMBL5935596 | 0.85 | PPARG (0.56) | PPARGFFAR1PPARACYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S LABORATORIES LIMITED | 2005-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032864-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B2 | PPARG 380/4885FFAR1 1350/4885PPARA 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.